Novartis Investigative Site
S.-Petersburg 198205
0 studies enrolling now · 14 studies all time
What they study most
Acute Decompensated Heart Failure, Acute Heart Failure, Acute Myocardial Infarction, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia, Cytokine Storm (Covid-19), Heart Failure With Reduced Ejection Fraction, Hypertension
Studies at this site
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
- Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
- Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia — Completed
- Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm — Completed
- 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis — Completed
- Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
- Global Non-interventional Heart Failure Disease Registry — Stopped early
- Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
- This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
- Efficacy and Safety of LCZ696A in Patients With Essential Hypertension — Completed
- LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction — Completed
- Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations — Completed
- Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed